The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Open accessAbstract
Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression. To advance this agenda, a meeting of key opinion leaders and experts in the metastasis and osteosarcoma communities was convened in Bethesda, Maryland. The goal of this meeting was to provide a “Perspective” that would establish a preclinical translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype. Although focused on osteosarcoma, the need for this perspective is shared among many cancer types. The consensus achieved from the meeting included the following: the biology of metastatic progression is associated with metastasis-specific targets/processes that may not influence grossly detectable lesions; targeting of metastasis-specific processes is feasible; rigorous preclinical data are needed to support translation of metastasis-specific agents into human trials where regression of measurable disease is not an expected outcome; preclinical data should include an understanding of mechanism of action, validation of pharmacodynamic markers of effective exposure and response, the use of several murine models of effectiveness, and where feasible the inclusion of the dog with naturally occurring osteosarcoma to define the activity of new drugs in the micrometastatic disease setting. Clin Cancer Res; 20(16); 4200–9. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tendency for osteosarcoma to metastasize to the lung is an outcome-defining complication that drives patient mortality and challenges clinicians 50 .”
From Osteosarcoma (2022) · cites this paper as [50]
In the citing paper
“Companion cell lines with enhanced lung colonization capacity, such as SaOS2-LM7, MG63.3 and 143B 209,210,211 , have enabled the study of metastasis-driving mechanisms 50,212 .”
From Osteosarcoma (2022) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Multistep Nature of Metastatic Inefficiency
Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N. I., Morris, V. L., Chambers, A. F., & Groom, A. C. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65628-3 · Cited by 1,283
Real-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
New signals from the invasive front
Christofori, G. (2006) · Nature · doi:10.1038/nature04872 · Cited by 1,018
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Self-citationMetastasis: recent discoveries and novel treatment strategies
Eccles, S. A., & Welch, D. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 737
Self-citationPreparing the “Soil”: The Premetastatic Niche
Kaplan, R. N., Rafii, S., & Lyden, D. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2407 · Cited by 681
Self-citationTranslation of new cancer treatments from pet dogs to humans
Paoloni, M., & Khanna, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2273 · Cited by 668
Self-citationSpontaneously Occurring Tumors of Companion Animals as Models for Human Cancer
Vail, D. M., & MacEwen, E. G. (2000) · Cancer Investigation · doi:10.3109/07357900009012210 · Cited by 533
Cited by
Sorted by citations
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S., Meltzer, P. S., & Gorlick, R. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,578
Self-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationOsteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Comparative oncology: what dogs and other species can teach us about humans with cancer
Schiffman, J. D., & Breen, M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0231 · Cited by 445
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 300
Metadata
- Authors
- Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., Merlino, G., Sorensen, P. H. B., Meltzer, P., Kirsch, D. G., Janeway, K. A., Weigel, B., Randall, L., Withrow, S. J., Paoloni, M., Kaplan, R., Teicher, B. A., Seibel, N. L., Smith, M., Üren, A., Patel, S. R., Trent, J., Savage, S. A., Mirabello, L., Reinke, D., Barkaukas, D. A., Krailo, M., & Bernstein, M.
- Affiliations
- National Institutes of Health (US)
- University of Illinois Urbana-Champaign (US)
- Albert Einstein College of Medicine (US)
- 17Cancer Biology and
- Children's Hospital of Philadelphia (US)
- Nationwide Children's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Kansas Medical Center (US)
- University of British Columbia (CA)
- Duke Medical Center (US)
- Harvard University (US)
- University of Minnesota (US)
- University of Utah (US)
- Colorado State University (US)
- Georgetown University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Translational Genomics Research Institute (US)
- University of Michigan (US)
- Children's Oncology Group (US)
- University of Southern California (US)
- Dalhousie University (CA)
- Corresponding author
- Fan, Timothy M.
- ORCID
- Fan, Timothy M.
- Gorlick, Richard
- Helman, Lee J.
- Kleinerman, Eugenie S.
- Adamson, Peter C.
- Houghton, Peter J.
- Tap, William D.
- Welch, Danny R.
- Steeg, Patricia S.
- Merlino, Glenn
- Sorensen, Poul H.B.
- Meltzer, Paul
- Kirsch, David G.
- Janeway, Katherine A.
- Weigel, Brenda
- Kaplan, Rosandra
- Teicher, Beverly A.
- Seibel, Nita L.
- Smith, Malcolm
- Üren, Aykut
- Patel, Shreyaskumar R.
- Trent, Jeffrey
- Savage, Sharon A.
- Mirabello, Lisa
- Reinke, Denise
- Krailo, Mark
- Bernstein, Mark
- Venue
- Clinical Cancer Research
- Published
- 2014-08-13
- Volume
- 20
- Issue
- 16
- Pages
- 4200-4209
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4134738
- OpenAlex
- W1974879801
- Cited by
- 178
- References
- 66
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 25 · 2023: 13 · 2022: 6 · 2021: 23 · 2020: 22 · 2019: 13 · 2018: 16 · 2017: 7 · 2016: 20 · 2015: 18 · 2014: 2
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010566, U10-CA98543, U24CA114766, U10CA180899, U10CA180886, U10CA098543, P30CA016672)
- National Institute of Allergy and Infectious Diseases (K02AI093866)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- osteosarcoma, lung metastasis, metastatic progression, drug development, pharmacodynamic biomarkers, mouse model, micrometastatic disease, mechanism of action
- MeSH terms
- Animals, Antineoplastic Agents, Bone Neoplasms, Disease Models, Animal, Dogs, Drug Evaluation, Preclinical, Humans, Osteosarcoma, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
